Resources - Scientific Posters
Fluorescence Intensity, FRET, and TR-FRET Homogeneous Assay Technologies from Invitrogen™ Validated on BioTek’s new Versatile Hybrid Microplate Reader, Synergy™ 4Download
January 23, 2008
Authors: Paul Held, Xavier Amouretti, BioTek Instruments; Kevin Lowitz, Mark Koeppel, Gary Prescott Invitrogen
This poster was presented at LabAutomation 2008.
Homogeneous assays have been used in drug screening and automated systems because they can provide scientific information without lengthy wash steps to remove unbound constituents. Several different fluorescence assay technologies offered by Invitrogen™ can be successfully incorporated as part of biomolecular screens for key drug target classes (e.g. kinases, nuclear hormone receptors, and G-protein coupled receptors). Omnia®, Z’-LYTE® and LanthaScreen™ are biochemical assays which can be utilized to assess kinase biology in vitro, and GeneBLAzer® is a cellular reporter-gene assay used to interrogate associated kinase signaling pathways in vivo. While these homogeneous assay technologies are all amenable to high-throughput screening campaigns, they employ widely different means of detection, including fluorescence intensity, FRET, and TR-FRET. Some assays use top read measurements, while others require that the signal be measured from the bottom of the microplate. Here we describe the use of the Synergy™ 4 Multi-Mode Microplate Reader with Hybrid Technology™ to perform this wide variety of Invitrogen™ screening assays. The patent pending Synergy 4 Reader has the capability of using either a tungsten-halogen or a xenon flash lamp as excitation light sources. In addition, the reader can use band-pass filters or monochromators for wavelength specificity without any mechanical changes to the reader. We will provide several examples of typical results obtained using these assay formats.
Z-LYTE®, Omnia®, GeneBLAzer® and CellSensor® are registered trademarks of Invitrogen. LanthaScreen™ and LiveBLAzer™ are trademarks of Invitrogen.